Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College o...( ALISO VIEJO Calif. May 5 /- Ambry...)

ALISO VIEJO, Calif., May 5 /PRNewswire/ -- Ambry Genetics Corp. announces the implementation of Comparative Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership with Baylor College of Medicine. Large chromosomal abnormalities that are associated with over 270 genetic syndromes can be easily identified via analysis of each 105K whole genome and mitochondrial array. The partnership with Baylor College of Medicine equips Ambry with an extensive library as a reference, as well as expert support for cytogenetics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

Ambry's CSO, Anja Kammesheidt states, "The oligonucleotide array was developed at Baylor College of Medicine and has proven to be an essential diagnostic tool. We are extremely pleased to be able to offer these same services now directly through our laboratory. Array CGH is becoming an integral part in any comprehensive genetic assessment."

The recent advancements in DNA microarrays are revolutionizing diagnostics by providing the ability to perform targeted and genome-wide studies (GWAS). Array CGH is used to detect genome-wide chromosomal imbalances with a single laboratory test consisting of multiple probes targeting virtually all disorders detected by traditional cytogenetics and fluorescent in situ hybridization (FISH). Array CGH is designed for patients with unexplained developmental delay, autism spectrum disorders, dysmorphic features, unexplained mental retardation, and/or multiple congenital anomalies. Each array contains 105K oligonucleotide probes, spaced at 30K through the genome with increased density at disease loci. Abnormalities are confirmed with other methods such as traditional FISH or MLPA. The test offers high resolution, sensitivity, enhanced clinical detection
'/>"/>